Lercadip

Lercanidipine, the active ingredient in Lercadip, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercadip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercadip, a dihydropyridine calcium channel blocker, is used to manage conditions within the hypertension disease family. - Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Isolated systolic hypertension: lowers elevated systolic pressure, improving vascular compliance. - Secondary hypertension (when caused by vascular resistance): assists in controlling pressure when other causes are addressed.

Lercadip may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, typically occurring shortly after dosing. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness without obvious cause.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of face, lips, tongue, or throat requiring urgent care. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reaction: rash, itching, or bronchospasm indicating hypersensitivity.

Before initiating therapy with Lercadip, several safety considerations should be observed. - Monitor blood pressure: ensure target levels are achieved and adjust dose if needed. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Caution in hepatic impairment: reduced metabolism may increase exposure. - Use with caution in elderly patients: increased sensitivity to vasodilatory effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercadip can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations and increase risk of hypotension. - Co‑administration with other potent antihypertensives (e.g., ACE inhibitors, beta‑blockers): can cause additive blood‑pressure lowering effects. - Grapefruit juice: can inhibit metabolism and elevate drug levels.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal impairment. - Diuretics: may enhance hypotensive response, requiring closer blood‑pressure monitoring.